The 7th (2015) International Asia Summit on Biomedical Research and Innovation was held in Shanghai

The 7th (2015) International Biomedicine
research and development innovation Asia Summit held in Shanghai sharing: Guide 7th International Biomedicine
research and development Innovation Asia Summit on January 20, 2015 21 in China, Shanghai, Mingjie Reinlee Hotel, for the rapid growth of Asia and emerging markets to inject positive energy for change, and around the Asian antibody tumor new drug research and development and clinical medical innovation, the healthy development of China's biopharmaceutical industry environment and new drug research and development product line and clinical treatment and other hot issues in-depth dialogue 7th (2015) International Biopharmaceutical Research and Innovation Asia Summit was held on January 20-21, 2015 at the Mingjie Wanli Hotel, Shanghai, China, and focused on "Therapeutic Cancer New Antibody Innovation Drug Research and Development and Clinical Medicine Innovation, from Johnson and Johnson Pharmaceuticals, Persimmon Squibb Pharmaceuticals, Novartis Pharmaceuticals, GlaxoSmithKline, Pfizer, Anjin Pharmaceuticals, Roche Pharmaceuticals, Syngent, Abao Pharmaceuticals, Shanghai Pharmaceuticals, Fosun Pharma, Hengrui Pharmaceuticals, Jiahe Biopharmaceuticals, Yangzijiang Pharmaceutical Group, CITIC Guojian Pharmaceuticals, Chinese Academy of Medical Sciences, Chinese Pharmaceutical University, China Pharmaceutical Industry Research Institute, University of California, Davis Medical College, Second Medical University Oriental Hepatobiliary Surgery Hospital, Shanghai Jiaotong University, Tianjin International Biopharmaceutical Joint Research Institute, Austrian, British Consulate General in Shanghai, and more than 200 other biopharmaceutical research and development leaders Injecting positive energy for rapidly growing research and development in Asia and emerging markets, and in-depth dialogue on hot issues such as research and development of new antibody tumors and clinical medicine innovation in Asia, the healthy development environment of China's biopharmaceutical industry and the product line of new drug research and development and clinical treatment Forum focused on new anti-tumor drugs, cardiovascular drugs, anti-diabetic drugs, neurodegenerative drugs, anti-infective drugs and other anti-major diseases of new drug innovation and clinical medical applications, the conference also held a pharmaceutical innovation and technology exhibition, at which Jin Weizhi Biotech Co., Ltd., Nanjing Kingsray Co., Ltd., Jingtiancheng Biotechnology (Beijing) Co., Ltd., Oda Kong Airport Biotechnology Co., Ltd., Shanghai Jitai Bio, Jianshun Biotech Co., Ltd., Cloud Health Technology And other units actively participate in the development of medical technology and technology two-day conference focused on the biopharmaceutical industry's focus on global innovation biopharmaceutical research and development innovation and human health, on antibody drugs, new vaccines, genetically engineered drugs, anti-infective drugs, anti-tumor drugs, cardiovascular system drugs and other anti-major disease drug research and development and clinical medical applications and Asian opportunities, the healthy development of the biopharmaceutical industry and other hot issues of the forum also explores the Asian pharmaceutical industry in the face of the global "heavy bomb" class biopharmaceutical pharmaceutical industry is about to meet the challenges of the peak of the development of new products To maximize the profit of new drug research and development, accelerate the transformation of new drug research and development from "laboratory" to clinical application, find the future trend of new drug research and development in Asia and win-win cooperation and innovation model, and inject change-driven positive energy and cooperation into rapidly growing research and development in Asia and emerging markets And around the development of new drugs and antibody drug innovation, China antibody drug industrialization how to break through the technical bottleneck? China's "13th Five-Year Plan" antibody drug development and industrial policy? Explore how China and Asia-Pacific countries- pharmaceutical enterprises - CRO, CMO companies, scientific research institutions can integrate research and development platform, improve antibody industrialization key technology breakthroughs, new drug technology patents and scientific and technological cooperation innovation model! Realizing a new round of therapeutic antibody drug innovation? During the session of the also held the "International Innovation Drug Research and Innovation Declaration Launch Ceremony", 45 well-known pharmaceutical executives and experts at home and abroad participated in the declaration ceremony of new drug innovation and technology, and at the beginning of the new year to new drug technology and drug development into new impetus More than 50 key delegates also visited The Amin Pharmaceuticals Asia Research and Development Center and attended the Navigation-Conference on The Regulation requirements for the Successful Management of Biodevelopment and Development, and listened to the presentations and innovative discussions by Paul Eienberg, Head of Global Medicine, Chief Medical Officer/Senior Vice President of Amin, Irene Deng, Head, Head, Head, Head, Chief Medical Officer, Roche China , Academician Liu Xinxuan of the Institute of Biochemistry and Cell of the Shanghai Academy of Sciences of the Chinese Academy of Sciences attended the meeting and gave a wonderful speech, sharing the latest research results of anti-tumor drugs, The Head of Biologics of Novartis (China) Biopharmaceutical Research Center, Zhijian Lu, PhD, Dr Ming-Qiang Zhang, Vice President of Research and Development in Asia Pacific of Amgen Corporation, Dr Ming-Qiang Zhang, Researcher/Vice President of the Chinese Academy of Pharmaceutical Industry Research, Shisheng Pharmaceutical Group Chief Scientific Officer Yan Jingwu, Professor of Chinese Medicine, Jian Wu, Professor Su Changqing of Oriental Hepatobiliary Surgery Hospital, Second Military Medical University, Professor Guo Wei, Chief Physician of the Ninth People's Hospital affiliated with Shanghai Jiaotong University School of Medicine, Prof DeZhengxian, Institute of Basic Medicine of the Chinese Academy of Medical Sciences, Zhou Xinhua, Ceo of Jiahe Biopharmaceutical Co., Ltd., Ph.D., Vice President of the Research Institute of Citic Guojian Pharmaceutical Co., Ltd in Shanghai, Jun Xiang, Ph.D, and Dr Jame Wu, Vice President of Perivane Squibb (China), Dr Cory William, Fu Jiemin, Vice President of Shanghai Fosun Pharmaceuticals (Group) Co., Ltd., and more than 20 other experts participated in the conference's thematic forum and thematic forum presentations and panel discussions to share innovative technologies for antibody new drug research and development and cancer clinical treatment Richard Wang PhD, Executive Director of the Central European Biomedicine Committee, and Stefan Kahl, Deputy Consul General of the Consulate General of Austria, addressed the meeting Dr Davy.chen, Executive Secretary of SEBMC at the Conference, said: China-EU Biomedicine Committee, the International Alliance for Innovative Drug Research and Development are committed to global innovative drug research and development and human health, promote biopharmaceutical technology and technological innovation applications, advocate the Global Drug Innovation Alliance initiative, and launch the Shanghai Declaration on Drug Research and Development Innovation and Human Health "Drug Discovery - Health Care Action Asia Declaration" public welfare activities, in China has been successfully held for seven consecutive years the International Biopharmaceutical Research and Innovation Asia Summit, and has organized more than 100 industry academic exchanges, technology applications, international cooperation theme activities, has been the Chinese-EUROPEAN government and the biopharmaceutical industry In the future, china and Asia's biopharmaceutical antibody industry market continues to grow, SEBMC will continue to build the Asian pharmaceutical biotechnology and medical science and technology exchange and cooperation platform to promote the pharmaceutical technology inventions and drug sustainable development recommended by the organizing committee of the collection (
0 ) (
0 )